KAKaouakib El Abida

Kaouakib El Abida

*This is an algorithmically generated author record based on publicly available information.

Kaouakib El Abida has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Alae Chda

    Laboratory of Microbial Biotechnology and Bioactive Molecules, Faculty of Sciences and Technologies Faculty, Sidi Mohamed Ben Abdellah University, P.O. Box 2202, Imouzzer Road, Fez, Morocco

    2 shared publications
  • Rachid Bencheikh

    Laboratory of Microbial Biotechnology and Bioactive Molecules, Faculty of Sciences and Technologies Faculty, Sidi Mohamed Ben Abdellah University, P.O. Box 2202, Imouzzer Road, Fez, Morocco

    2 shared publications
  • Youssef Mahou

    Laboratory of Microbial Biotechnology and Bioactive Molecules, Faculty of Sciences and Technologies Faculty, Sidi Mohamed Ben Abdellah University, P.O. Box 2202, Imouzzer Road, Fez, Morocco

    2 shared publications
  • Abdellatif Boukir

    Laboratory of Applied Chemistry, Faculty of Sciences and Technology of Fez, Sidi Mohamed Ben Abdellah University, B.P. 2202, Imouzzer Road, Fez, Morocco

    1 shared publication
  • Angela Tesse

    Nantes University, Inserm, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, France

    1 shared publication
  • Aziz El Bouri

    Institut de Criminalistique de La Gendarmerie Royale, BP 6597 Rabat-Instituts, Rabat, CP 10000, Morocco

    1 shared publication

Latest Publications

  • Open Access

    Investigation on the gastrointestinal properties of ethanolic extract of Cannabis sativa through in vivo and in vitro approaches

    by Alae Chda, Youssef Mahou, Youssra Znata, Hinde El Fatemi, Abdellatif Boukir, Samir Ananou, Kaouakib El Abida, Rachid Bencheikh

    Introduction: For thousands of years, Cannabis sativa has been used for its medical and recreational benefits. Nowadays, there is an increasing interest in the use of C. sativa and its non-psychoactive products/effects to treat certain diseases. This study was conducted to examine the gastrointestinal effects of a sequential ethanolic fraction of C. sativa threshing residues (EFCS). Methods: In vivo and in vitro approaches were used to investigate the gastrointestinal properties of EFCS. Antidiarrheal, antibacterial, spasmodic, laxative, and antiulcer effects were tested respectively against castor oil induced diarrhea, disc diffusion method, isolated tissue preparations, charcoal transit time, and ethanol induced ulcer model. Results: EFCS induced a spasmodic effect on an isolated rabbit jejunum, which was inhibited by atropine and verapamil. Moreover, under free calcium conditions, the effect of EFCS was significantly reduced. The acute toxicity assay in female and male mice showed that EFCS was a safe product. Additionally, EFCS like loperamide presented antidiarrheal effect in mice and inhibited intestinal fluid secretions. Unlike the standard drug (loperamide), EFCS increased the motility of the intestinal transit. Furthermore, EFCS showed a protective effect against gastric ulcers induced by ethanol in mice and exhibited antimicrobial properties against Bacillus cereus strains. Conclusion: The results of this study reveal that EFCS possesses anti-diarrheal, antibacterial, spasmodic, laxative, and anti-ulcer activities. EFCS has potential therapeutic use against gastrointestinal diseases. Also, our work values the non-psychoactive products of C. sativa.


  • Open Access

    Vasorelaxant Effect of Moroccan Cannabis sativa Threshing Residues on Rat Mesenteric Arterial Bed is Endothelium and Muscarinic Receptors Dependent

    by Youssef Mahou, Alae Chda, Nour Eddine Es-Safi, Angela Tesse, Nezha Fettoukh, Aziz El Bouri, Hamid Stambouli, Kaouakib El Abida, Rachid Bencheikh

    Introduction. Ethanolic fraction of Moroccan Cannabis sativa threshing residues (EFCS) was evaluated for its vasorelaxant activity. The current work aims to identify the active metabolites in the ethanolic fraction of the EFCS and illustrate their mechanism of action. Methods. Free radical scavenging capacity of EFCS was assessed using DPPH method. The EFCS vasodilation activities in phenylephrine‐precontracted isolated rat mesenteric arterial beds were investigated in presence of L‐NAME (nitric oxide synthase inhibitor), indomethacin (cyclooxygenase inhibitor), potassium channel blockers (namely tetraetylamonium, barium chloride, and glibenclamide), and atropine. Nitric oxide vascular release was measured by electron paramagnetic resonance (EPR) using a spin trap in rat aortic rings. Results. EFCS induced dose‐dependent vasorelaxation on mesenteric vascular bed. Incubation of the preparations with L‐NAME, ODQ (a soluble guanylyl cyclase inhibitor), or potassium channel blockers reduced the fall of perfusion pressure caused by EFCS. Endothelial denudation or atropine abolished the EFCS’s vasorelaxant effect, suggesting involvement of muscarinic receptors and endothelium‐relaxing factors. The extract induced nitric oxide release in aortic rings in a similar manner as acetylcholine suggesting an effect of EFCS on the muscarinic receptor and the conductance arteries. Chemical investigation of EFCS identified potential active components namely apigenin and derivatives of luteolin skeleton and also additional components such as neophytadiene, squalene, and β‐sitosterol. In conclusion, the vasorelaxant effect of EFCS on rat mesenteric arterial bed, which is dependent of muscarinic receptor activation, nitric oxide, and EDHF, can account for potential therapeutic use against high blood pressure related cardiovascular diseases.